RPE65-Related Retinopathy: Comprehensive Research Report

MONDO ID: MONDO:0100368 Category: Mendelian, autosomal recessive (rare autosomal dominant form also reported) Key OMIM entries: #204100 (Leber Congenital Amaurosis 2, LCA2), #613794 (Retinitis Pigmentosa 20, RP20), *180069 (Retinoid Isomerohydrolase RPE65, the gene locus)

1. Disease Information

Overview. RPE65-related retinopathy is the umbrella term for a spectrum of autosomal recessive (and, rarely, autosomal dominant) inherited retinal dystrophies caused by biallelic (or, for one specific variant, heterozygous) pathogenic variants in RPE65, which encodes the retinal pigment epithelium (RPE)-specific isomerohydrolase that regenerates the visual chromophore 11-cis-retinal. The clinical spectrum spans a continuum of severity: Leber congenital amaurosis (LCA2) at the severe end, early-onset severe retinal dystrophy (EOSRD) in the middle, and RPE65-associated retinitis pigmentosa (RP20), sometimes with juvenile onset, at the milder end — "the three phenotypes of autosomal recessive RPE65-related retinal degeneration, from most severe to mildest, are Leber congenital amaurosis (LCA), early-onset severe retinal dystrophy (EOSRD), and juvenile retinitis pigmentosa (RP)" (GeneReviews, NBK549574). This is the first inherited retinal disease with an FDA/EMA-approved gene-replacement therapy (voretigene neparvovec-rzyl, Luxturna).

Key identifiers:

Synonyms: RPE65-associated retinal dystrophy; RPE65-mediated inherited retinal disease (RPE65-IRD); Leber congenital amaurosis type 2 (LCA2); RPE65 deficiency; Retinitis pigmentosa 20 (RP20); autosomal recessive childhood-onset severe retinal dystrophy (RPE65 type); retinoid isomerohydrolase deficiency.

Evidence basis: This report draws on OMIM/GeneReviews disease-level syntheses, structured registries (Orphanet, ClinVar/ClinGen), large multi-center natural-history and clinical-trial cohorts (e.g., the Phase 1/3 voretigene neparvovec program), and individual case reports/small case series for variant-level detail — the evidence tiers differ and are noted per claim.

2. Etiology

Disease causal factor: RPE65-related retinopathy is monogenic. Biallelic loss-of-function or hypomorphic variants in RPE65 (chromosome 1p31.3) cause the autosomal recessive spectrum (LCA2/EOSRD/RP20). A single specific missense variant, p.Asp477Gly (D477G), causes a distinct autosomal dominant late-onset retinitis pigmentosa through a toxic gain-of-function/aggregation mechanism rather than simple haploinsufficiency (see §4 and §6).

Genetic risk factors: - Causal variants: >150 distinct pathogenic RPE65 variants reported across missense, nonsense, frameshift, splice-site, and small in-frame indel classes (ClinVar; PMC7016655 "Pathogenicity Reclassification of RPE65 Missense Variants"). - Modifier genes: No well-established modifier locus is confirmed for RPE65-retinopathy specifically, unlike CEP290-LCA (where AHI1 has been proposed as a modifier; PMC3048164). Phenotypic variability among biallelic-genotype-matched patients is well documented but its genetic basis is not fully resolved. - Consanguinity: Increases homozygosity for rare recessive RPE65 alleles in populations/families with high consanguinity rates; multiple case series (e.g., from the Russian Federation, PMC10671290; East Asian cohorts, PMC9644481) report founder/recurrent alleles. - Founder alleles: Population-specific recurrent variants are documented; East Asian carrier frequency was estimated at ~0.10% (11/10,919 alleles) in gnomAD/KRGDB-derived East Asian samples and ~0.06% in Koreans specifically (PMC9644481, Orphanet J Rare Dis 2022).

Environmental risk factors: None established as causal — this is a purely Mendelian disease. However, ambient light/luminance exposure modulates phenotype severity in the dominant D477G form: "The interplay of environmental luminance and genetics in the retinal dystrophy induced by the dominant RPE65 mutation" (PMC8931212, PNAS 2022) demonstrates that light exposure interacts with the D477G genotype to determine degeneration severity in animal models, a rare example of gene-environment interaction in an otherwise monogenic disease.

Protective factors: No genetic protective variants are established. Reduced UV/blue-light exposure is biologically plausible as ameliorating in the dominant form (lipofuscin/A2E-related photo-oxidative mechanisms, see §6) but is not established as a clinical protective intervention through controlled trials.

Gene-environment interactions: Best characterized for D477G — see PMC8931212 above; not established for the biallelic recessive forms, where disease is fully penetrant regardless of environment.

3. Phenotypes

Core phenotype set (by category)

Symptoms/signs — visual: | Phenotype | Frequency/notes | Suggested HP term | |---|---|---| | Severe congenital/infantile vision loss (LCA) or progressive vision loss (EOSRD/RP) | Nearly universal for LCA form; onset in infancy | HP:0000618 (Blindness) / HP:0000505 (Visual impairment) | | Nystagmus (typically pendular) | Very common, often presenting sign in infancy | HP:0000639 (Nystagmus) | | Nyctalopia (night blindness) | "Most patients with RPE65 mutations are profoundly night blind"; earliest symptom, often before central vision loss, even in RP-only phenotype | HP:0000662 (Nyctalopia) | | Photophobia | Common | HP:0000613 (Photophobia) | | Sluggish or near-absent pupillary light reflex | Frequent in LCA | HP:0007686 (Abnormal pupillary function) / HP:0008070 (Sluggish pupillary response) | | Oculodigital sign (eye-poking/pressing/rubbing) | Common in infantile LCA presentations | HP:0006990 (Eye poking) | | High hyperopia | Frequent | HP:0008515 (Hyperopia) | | Keratoconus | Reported, secondary to chronic eye rubbing | HP:0000563 (Keratoconus) | | Cataract | Reported as a secondary/late finding | HP:0000518 (Cataract) | | Strabismus | Common | HP:0000486 (Strabismus) | | Reduced/constricted visual field | Progressive | HP:0000603 (Constriction of peripheral visual field) | | Variable/abnormal fundus appearance | "Variable appearance to the fundus" — ranges from near-normal in infancy to bone-spicule pigmentary changes, attenuated vessels, optic disc pallor, and macular atrophy with progression | HP:0007663 (Reduced visual acuity) as functional correlate; HP:0000580 (Pigmentary retinopathy); HP:0000556 (Retinal dystrophy) | | Macular atrophy/coloboma-like macular changes | More characteristic in later stages and in some genotypes | HP:0007401 (Macular atrophy) |

Laboratory/electrophysiologic abnormality (functional): - Electroretinogram (ERG): severely reduced or non-recordable (rod and cone responses) — "the ERG is severely reduced or non-recordable" in RPE65-LCA/EOSRD. In the milder RP20 phenotype ERG may remain partially recordable, especially earlier in the disease course. Suggested term: HP:0000513 (Abnormal electroretinogram)/ more specific HP:0000662-associated functional test findings. - Full-field stimulus threshold (FFST): markedly elevated dark-adapted thresholds (used as a primary trial endpoint; log-unit improvements of ~2 log10 cd·s·m⁻² reported post-gene-therapy).

Phenotype characteristics: - Age of onset: LCA form — onset in infancy, typically within the first year of life (congenital or near-congenital); EOSRD — early childhood; RP20 (autosomal recessive juvenile/childhood RP) — onset from childhood into adolescence; the OMIM RP20 family description notes "onset of severe visual impairment was between 3 and 7 years of age, with night blindness being a typical and early symptom in all patients." The autosomal dominant D477G form is distinctly later-onset ("advanced late-onset retinitis pigmentosa," PMC7228561). - Severity: Generally severe (profound, near-blind) in LCA; variable but progressive in EOSRD/RP. - Progression: Progressive in all forms; central vision is often relatively preserved longer than peripheral/night vision early on, but declines with age — "night blindness is one of the earliest symptoms but patients tend to suffer central visual loss later." In a large natural-history case series, children aged 4–10 years already had severe visual impairment (mean visual acuity ~20/126). - Frequency among affected individuals: Night blindness and nystagmus are present in nearly all cases; keratoconus and cataract are present in a minority and tend to be later complications.

Quality of life impact: Profound vision loss from infancy has major developmental, educational, and psychosocial consequences (mobility, literacy via Braille/assistive technology, dependence). Gene-therapy trials formally captured functional vision (multi-luminance mobility testing, MLMT) and quality-of-life instruments, showing meaningful gains post-treatment, "particularly in younger patients" (per long-term follow-up data).

4. Genetic/Molecular Information

Gene: RPE65 — Retinoid Isomerohydrolase RPE65; HGNC:10294; chromosome 1p31.3 (varies slightly by source, commonly cited 1p31); NM_000329.3 is the reference transcript used in clinical variant nomenclature.

Causal genes/loci: RPE65 is the sole causal gene for this entity by definition. OMIM lists two disease associations: #204100 LCA2 (autosomal recessive) and #613794 RP20 (autosomal recessive); a separate autosomal dominant RP phenotype (sometimes designated RP87 in more recent OMIM nomenclature) is caused specifically by the heterozygous D477G variant.

Variant spectrum and classification: - Types: missense (the largest category), nonsense, frameshift (e.g., c.106del predicted to cause a frameshift and premature stop, leading to nonsense-mediated decay), splice-site, and small in-frame deletions/insertions. - ACMG/ClinVar classification: Variants are individually curated pathogenic/likely pathogenic/VUS per ACMG-AMP criteria; a ClinGen RPE65-specific Variant Curation Expert Panel specification exists (cspec.genome.network/cspec/ui/svi/doc/GN120), refining general ACMG rules for this gene. A dedicated reclassification effort addressed missense VUS: "Pathogenicity Reclassification of RPE65 Missense Variants Related to Leber Congenital Amaurosis and Early-Onset Retinal Dystrophy" (PMC7016655). - Population allele frequency: Individual pathogenic variants are each very rare in gnomAD (e.g., c.1039C>T p.Arg347Cys reported at ~0.00000124 allele frequency, 5/1,179,740 alleles, in European non-Finnish gnomAD), consistent with a rare recessive disease; aggregate carrier frequency in East Asians was estimated at ~0.10%. - Somatic vs. germline: Exclusively germline; no somatic mosaicism mechanism described for this disease. - Functional consequences: - Most recessive loss-of-function alleles (nonsense, frameshift, canonical splice-site) abolish or near-abolish isomerohydrolase enzymatic activity — complete loss of function. - Many missense alleles are hypomorphic (partial loss of function), correlating with the milder EOSRD/RP20 end of the phenotypic spectrum rather than LCA — see the "novel RPE65 hypomorph" functional study (PMC5015590). - The dominant D477G variant does not act by simple haploinsufficiency: functional studies show "the adverse cellular consequence of the D477G mutant coexpressed with WT-RPE65 far exceeded that of losing a single allele of WT-RPE65," and structural/biochemical work indicates D477G forms an aggregation-prone surface that induces abnormal protein–protein interactions with wild-type RPE65, driving RPE65 protein degradation and reduced isomerase activity beyond what simple heterozygous loss would predict — i.e., a toxic/dominant-negative gain-of-function mechanism (PMID:29659842, Hum Mol Genet 2018; PMC7760593/PMID:33261050).

Modifier genes: None definitively established for the RPE65-recessive spectrum.

Epigenetic information: No disease-specific DNA methylation/histone modification mechanism is established as causal; this is a classic monogenic enzymatic deficiency disease.

Chromosomal abnormalities: Not a recognized mechanism — disease results from point mutations/small indels within RPE65, not large structural rearrangements, though whole-gene or exonic deletions have occasionally been reported as pathogenic alleles.

Ontology suggestions: Gene — hgnc:10294 (RPE65); Molecular function — GO:0003920 (retinoid isomerohydrolase activity / GO:0033760 "retinal isomerase activity" umbrella term), GO:0033748 (bisretinoid catabolism, indirectly relevant); relevant CHEBI terms: CHEBI:17561 (retinol), CHEBI:17278 (all-trans-retinyl ester), CHEBI:17885 (11-cis-retinal).

5. Environmental Information

RPE65-related retinopathy is not an infectious, toxin-induced, or classically "environmental" disease — it is monogenic. The only substantiated environmental interaction is:

• Ambient luminance/light exposure as a phenotype modifier specifically for the dominant D477G allele (PMC8931212, PNAS 2022) — higher-light environments were associated with greater retinal dystrophy severity in genetically modeled systems, implicating light-driven photo-oxidative stress (via the retinoid/lipofuscin cycle, see §6) as an aggravating factor superimposed on the genetic lesion.
• Vitamin A/retinoid status: Because RPE65 sits in the core vitamin A (retinoid) visual cycle, systemic vitamin A metabolism is mechanistically intertwined with the RPE65 defect, though dietary vitamin A supplementation has not been shown to correct the enzymatic block (unlike some other IRDs, e.g., Refsum disease with dietary phytanic acid restriction). This is the pharmacological rationale instead for exogenous synthetic retinoid replacement therapy (QLT091001/9-cis-retinyl acetate; see §12).
• No infectious agents are implicated.
• Lifestyle factors: No behavioral risk-modifying factor (smoking, diet, exercise) has controlled-trial evidence in this specific disease, though general retinal-health advice (UV protection) is plausible extrapolation from the light-luminance mechanistic data above, primarily relevant to D477G carriers.

Suggested ECTO term if curating an environmental modifier edge: an ambient/ocular light-exposure term (e.g., ECTO class for "light exposure") linked specifically to the D477G pathophysiology node, with environmental_effect: EXACERBATES.

6. Mechanism / Pathophysiology

Ordered causal chain (recessive/loss-of-function form — LCA2/EOSRD/RP20)

1. Biallelic loss-of-function or hypomorphic pathogenic variants in RPE65 lead to absent or markedly reduced RPE65 retinoid isomerohydrolase enzymatic activity in the retinal pigment epithelium (demonstrated biochemically; PMID:16116091, PNAS 2005 — "RPE65 is the isomerohydrolase in the retinoid visual cycle").
2. Loss of isomerohydrolase activity results in failure to convert all-trans-retinyl ester to 11-cis-retinol within the RPE cell, the rate-limiting step of the retinoid ("visual") cycle.
3. Absence of 11-cis-retinol/11-cis-retinal leads to depletion of functional visual chromophore available to combine with opsin apoprotein in rod and cone outer segments, so rhodopsin (rods) and cone opsins cannot be regenerated after bleaching.
4. Chromophore-free ("apo-") opsin causes two convergent downstream consequences, demonstrated to be mechanistically distinct in rods versus cones:
5. 4a. Rods: unliganded rod opsin is intrinsically unstable/constitutively signals abnormally and triggers a Bax-dependent apoptotic pathway in rod photoreceptors (PMC2720534, "Bax-Induced Apoptosis in Leber's Congenital Amaurosis: A Dual Role in Rod and Cone Degeneration"), together with upregulation of lysosomal-mediated autophagic gene expression contributing to early rod apoptosis in Rpe65⁻/⁻ mice (PMID:22227450).
6. 4b. Cones: cone photoreceptor death proceeds via a Bax-independent mechanism — "early loss of cones was not prevented in Rpe65⁻/⁻/Bax⁻/⁻ mice, indicating that pro-apoptotic Bax was not involved in the pathogenesis of cone cell death in Rpe65-deficient mice" — implicating a separate degenerative cascade (proposed to relate to chronic unliganded-cone-opsin signaling/ER stress rather than classical Bax-mediated apoptosis) and explaining the disproportionately early, severe cone dysfunction seen clinically even though rods normally vastly outnumber cones.
7. Progressive rod and (via the separate pathway) cone photoreceptor apoptosis results in outer-segment shortening/disorganization and eventual photoreceptor cell loss, detectable clinically as thinning of the outer nuclear layer/ellipsoid zone on OCT and as non-recordable or severely reduced ERG amplitudes.
8. Concurrently, accumulation of un-isomerized all-trans-retinyl esters and derived bis-retinoid byproducts (notably A2E, a diretinal-phosphatidylethanolamine conjugate formed from all-trans-retinal condensing with phosphatidylethanolamine in photoreceptor outer segments and subsequently phagocytosed into the RPE) accumulates as RPE lipofuscin. A2E cannot be enzymatically degraded, perturbs RPE lysosomal membrane integrity and phagolysosomal function (inhibiting phagolysosomal degradation of photoreceptor phospholipid), and confers susceptibility to blue-light-induced RPE apoptosis — providing a secondary, light-exacerbated toxic mechanism to RPE and photoreceptor injury superimposed on the primary chromophore-deprivation mechanism. (Note: in the RPE65-null state itself, lipofuscin/A2E accumulation is reduced relative to wild type because retinyl-ester substrate is not being processed through the normal cycle at all — the Leu450Met Rpe65 hypomorphic mouse variant, by contrast, shows reduced A2E via slowed cycle flux, PMID:15277666 — so the lipofuscin/A2E axis is most clinically relevant to milder hypomorphic and to the light-modulated dominant D477G phenotype rather than to null LCA2.)
9. Clinically, this cascade manifests as profound infantile/childhood visual impairment, nystagmus, night blindness, and a non-recordable or severely subnormal ERG (steps 1→3 dominate the earliest, most severe LCA presentation; steps 4→6 drive the progressive component seen even in successfully gene-corrected retina, explaining why continued photoreceptor loss can occur after gene therapy despite restored chromophore supply — see §12).

Branch: dominant D477G mechanism

1′. The heterozygous D477G missense variant produces a structurally abnormal RPE65 protein with an aggregation-prone surface. 2′. This mutant protein engages in atypical protein–protein interactions with co-expressed wild-type RPE65, causing wild-type RPE65 protein degradation and a net reduction in cellular isomerase activity that exceeds the reduction expected from simple loss of one functional allele (i.e., not classical haploinsufficiency) — a dominant-negative/toxic gain-of-function mechanism (PMID:29659842; PMID:33261050). 3′. The resulting partial visual-cycle impairment, superimposed on and exacerbated by ambient light/luminance exposure (PMC8931212), leads to a milder, later-onset retinitis pigmentosa phenotype than the biallelic null state.

Categories covered

• Molecular pathways: Retinoid (visual) cycle — RPE65 catalyzes the committed isomerization/hydrolysis step converting all-trans-retinyl ester → 11-cis-retinol (KEGG: Retinol metabolism, hsa00830; Reactome: "Visual phototransduction").
• Cellular processes: Apoptosis (rod: Bax-dependent, GO:0006915/GO:0043523 negative regulation of neuron apoptotic process is disrupted; cone: Bax-independent, distinct pathway); autophagy/lysosomal gene upregulation (GO:0006914 autophagy); phagolysosomal dysfunction in RPE.
• Protein dysfunction: Loss of enzymatic function (null/hypomorphic alleles) vs. misfolding/aggregation-driven dominant-negative toxicity (D477G).
• Metabolic changes: Disrupted vitamin A/retinoid metabolism; secondary accumulation of retinyl esters and altered bis-retinoid (A2E) flux.
• Tissue damage mechanisms: Chronic photo-oxidative stress from lipofuscin/A2E accumulation, particularly light-exposure-dependent.
• Biochemical abnormality: Isomerohydrolase enzyme deficiency — the defining lesion.
• Molecular profiling: Biochemical/functional assays (HPLC-MS/MS quantification of retinoids) are used for variant functional characterization (e.g., PMC7138296-style approach applied across LCA genes); RPE65 protein expression studies in HEK293/insect-cell heterologous systems and iPSC-derived RPE/retinal organoids from patients (PMC6749091) recapitulate reduced isomerase activity and photoreceptor phenotypes in vitro.

Suggested GO terms: GO:0003920 (retinal isomerase activity — closest functional GO term for the isomerohydrolase activity), GO:0009416 (response to light stimulus), GO:0007601 (visual perception), GO:0006915 (apoptotic process), GO:0043524 (negative regulation of neuron apoptotic process). Suggested CL terms: CL:0000210 (photoreceptor cell), CL:0000604 (retinal rod cell), CL:0000573 (retinal cone cell), CL:0002586 (retinal pigment epithelial cell). Suggested CHEBI terms: CHEBI:17561 (retinol), CHEBI:17885 (11-cis-retinal), CHEBI:17278 (retinyl ester, generic), lipofuscin/A2E lacks a precise CHEBI ID commonly used in curation — record as free text if no exact match.

7. Anatomical Structures Affected

Organ level: - Primary organ: eye — specifically the neurosensory retina and retinal pigment epithelium (UBERON:0000966 retina; UBERON:0002050 retinal pigment epithelium is not a standard distinct UBERON ID — RPE is typically captured via CL:0002586 cell type plus UBERON:0000966 retina, or UBERON:0001782 (choroid)-adjacent structures depending on ontology version). - Secondary involvement: cornea (keratoconus secondary to chronic eye-rubbing, UBERON:0000362 cornea), lens (cataract, UBERON:0001845), extraocular muscles (strabismus, secondary to poor fixation). - Body systems: primarily the visual/sensory system (nervous system extension); no systemic organ involvement — RPE65-retinopathy is a non-syndromic, eye-limited disease (distinguishing it from syndromic ciliopathy-associated LCA genes such as CEP290).

Tissue and cell level: - Neurosensory retina — outer nuclear layer (photoreceptor cell bodies), photoreceptor inner/outer segments. - RPE monolayer — site of the primary enzymatic defect (CL:0002586, retinal pigment epithelial cell). - Affected cell populations: rod photoreceptors (CL:0000604) and cone photoreceptors (CL:0000573), both degenerate, via distinct mechanisms (§6); RPE cells (CL:0002586) accumulate lipofuscin/A2E.

Subcellular level: - RPE smooth endoplasmic reticulum — site of RPE65 enzymatic activity (GO Cellular Component: GO:0005783 endoplasmic reticulum; RPE65 is a microsomal membrane-associated protein). - RPE lysosomes — site of A2E/lipofuscin accumulation and impaired phagolysosomal degradation (GO:0005764 lysosome). - Photoreceptor outer segment discs — site of opsin/chromophore complex formation and of A2E precursor formation (GO:0001750 photoreceptor outer segment).

Localization: Bilateral, generally symmetric involvement (as expected for a systemic monogenic enzymatic deficiency rather than a focal lesion); no lateralization pattern reported.

8. Temporal Development

Onset: - LCA2: congenital/infantile — visual manifestations typically apparent within the first year of life; frequently the presenting complaint is roving eye movements/nystagmus and lack of visual fixation noticed by caregivers in early infancy. - EOSRD: early childhood onset, intermediate severity. - RP20 (recessive, juvenile RP phenotype): onset in one documented family series between ages 3–7 years, with night blindness as the earliest and most consistent symptom. - Dominant D477G RP: distinctly later-onset, described in the literature as "advanced late-onset retinitis pigmentosa" (PMC7228561), i.e., adult-onset relative to the recessive forms. - Onset pattern: insidious/progressive rather than acute, though the profound congenital deficit in LCA2 can appear as an abrupt discovery at birth/infancy even though the underlying enzymatic lesion is present from conception.

Progression: - Disease course is chronic and progressive across the spectrum; there is no spontaneous remission. - Natural history: night blindness (rod-pathway dysfunction) typically precedes and is more severe/earlier than central (cone-mediated) visual loss, which develops later but can still occur in the first decade — "children ages four to ten years in the largest case series had severe visual impairment (mean visual acuity: 20/126)." - Progression rate: variable across the recessive spectrum (LCA fastest/most severe from birth; RP20 slower); within any one genotype, phenotype severity can still vary between patients, suggesting genetic background or environmental modifiers. - Disease duration: lifelong, chronic — no natural resolution; some patients with milder hypomorphic alleles retain functional (if severely reduced) vision into adulthood, providing the therapeutic window exploited by gene therapy. - Even after gene augmentation therapy restores chromophore-generating capacity, continued photoreceptor degeneration has been documented in surviving but already-compromised retina (see §12) — i.e., the enzymatic correction does not fully halt an already-initiated degenerative process in retina beyond a certain disease stage, underscoring the importance of the "critical period"/treatment-timing concept below.

Patterns: - No remission pattern (progressive monogenic disease). - Critical period for intervention: A central concept in this disease's management is that gene therapy is most effective when administered to retina with sufficient viable photoreceptors remaining — "treated locations having more than 63% of normal photoreceptors showed robust treatment-related retention of photoreceptors in the long term, while treated regions with less retained photoreceptors at the time of the intervention showed progressive degeneration similar to untreated regions" — establishing a structural/temporal window beyond which restoring the enzyme cannot rescue already-committed-to-death photoreceptors. This underlies current gene-therapy eligibility criteria requiring sufficient viable retinal area (see §10, §12).

9. Inheritance and Population

Epidemiology: - LCA overall (all genes combined) affects an estimated 1 in 30,000 to 1 in 81,000 live births; RPE65 accounts for roughly 5–10% of LCA cases. - Retinitis pigmentosa overall affects 1 in 3,000–7,000 people; autosomal recessive RP accounts for ~5–20% of RP, and RPE65 accounts for roughly 2–5% of autosomal recessive RP. - In a multi-center inherited-retinal-dystrophy cohort of 2,240 patients, 18 (0.8%) had RPE65-related disease: 38.8% presenting as LCA, 22.2% as RP, 33.3% as severe early-onset retinal dystrophy, and 5.5% as congenital stationary night blindness-like presentation — illustrating the phenotypic breadth captured under one genotype. - In a Russian Federation cohort, RPE65-associated retinopathy accounted for 5.3% (25/474) of molecularly confirmed inherited retinal disease cases (PMC10671290). - Global disease burden: given the rarity, RPE65-retinopathy is classified as an ultra-rare disease; precise worldwide point-prevalence figures analogous to Orphanet's numeric prevalence bands are not consistently published as a single figure, but the above LCA/RP fraction data support an estimated worldwide prevalence in the range of roughly 1–2 per 100,000 to 1 per 1,000,000 (consistent with an Orphanet "1-9 / 1,000,000" or similarly rare band; a precise Orphanet numeric class was not independently confirmed in this search).

Inheritance pattern: Predominantly autosomal recessive (biallelic pathogenic variants — homozygous or compound heterozygous); a distinct, well-characterized autosomal dominant form exists caused specifically by the heterozygous D477G variant.

Penetrance: The recessive forms are essentially fully penetrant given biallelic pathogenic genotypes (consistent with a classic enzyme-deficiency Mendelian disease). Penetrance/expressivity of D477G dominant disease is modulated by environmental light exposure (§2, §6), suggesting incomplete or variable penetrance/expressivity for that specific allele depending on environmental luminance history — an unusual and specifically documented gene-environment penetrance modifier for a monogenic retinal disease.

Expressivity: Variable — even among patients with identical or similar biallelic genotypes, phenotype severity (LCA vs. EOSRD vs. RP20) and rate of progression differ, and macular morphology differs by causal gene even within the LCA differential (RPE65 vs. CEP290 vs. GUCY2D vs. AIPL1 patients show distinguishable macular phenotypes), suggesting genotype is only a partial predictor.

Genetic anticipation: Not described — RPE65-retinopathy is not a repeat-expansion disorder.

Germline mosaicism: Not specifically documented as a recurring feature in RPE65-retinopathy literature reviewed; general recessive-disease recurrence-risk counseling principles apply (25% recurrence risk per pregnancy for carrier parents of an affected homozygous/compound heterozygous child).

Founder effects: Documented at the population level — recurrent/founder pathogenic alleles reported in specific populations (East Asian, Russian, and other cohorts cited above), though no single globally dominant founder allele analogous to some other IRD genes has been established across all populations.

Consanguinity role: As with other rare autosomal recessive IRDs, consanguineous unions increase homozygosity for rare pathogenic RPE65 alleles and are commonly noted in case series from populations with higher consanguinity rates.

Carrier frequency: Estimated ~0.10% in East Asians (gnomAD/KRGDB combined) and ~0.06% in Koreans specifically (PMC9644481); carrier frequencies elsewhere are lower given the gene's overall rarity and the population-specific nature of most pathogenic alleles.

Population demographics: No strong sex predilection is reported (autosomal, not X-linked); no major geographic endemicity beyond population-specific founder-allele effects; age distribution of affected individuals spans from infancy (LCA presentation) through adulthood (dominant D477G presentation), reflecting the phenotypic spectrum rather than a single onset age.

10. Diagnostics

Clinical tests: - Electroretinography (ERG): central diagnostic test — severely reduced or non-recordable scotopic and photopic responses in LCA/EOSRD; may show residual but markedly subnormal responses in milder RP20/dominant D477G presentations, especially earlier in the disease course. - Optical coherence tomography (OCT): assesses outer nuclear layer/ellipsoid zone thickness and residual photoreceptor structure — critical for gene-therapy eligibility assessment (identifying sufficient viable retina) and for longitudinal monitoring of structural decline post-treatment. - Fundus autofluorescence: can show altered patterns related to lipofuscin/RPE status, useful in phenotyping and monitoring. - Full-field stimulus threshold (FFST) testing: dark-adapted psychophysical threshold test — the primary functional endpoint in the pivotal voretigene neparvovec trials, given the non-recordable ERG in many LCA patients makes ERG unsuitable as a treatment-response endpoint. - Multi-luminance mobility testing (MLMT): a functional-vision obstacle-course assay developed specifically for the voretigene neparvovec trials, assessing ability to navigate a course at graded light levels — became a novel, disease-specific, FDA-recognized functional endpoint. - Visual field testing: Goldmann or other perimetry to assess peripheral field constriction, where central fixation/cooperation allow. - Biopsy/histopathology: not routinely performed given the availability of genetic diagnosis; historical/postmortem histopathology contributed to early understanding of photoreceptor/RPE degeneration.

Genetic testing: - Recommended approach: targeted RPE65 single-gene sequencing when clinical phenotype (early nyctalopia, ERG pattern) is suggestive, or more commonly as part of a multi-gene inherited retinal disease (IRD)/LCA panel given overlapping phenotypes among the ~20+ LCA-associated genes (see differential diagnosis below) — panel-based next-generation sequencing (NGS) is now first-line given genetic and phenotypic heterogeneity of LCA/EOSRD, with whole exome sequencing (WES) as a common escalation when panels are non-diagnostic, given the diagnostic yield reported (e.g., PMID:28966547, "Diagnostic application of clinical exome sequencing in Leber congenital amaurosis"). - Whole genome sequencing (WGS): used in research/tertiary settings when exome-negative, to capture deep intronic or structural variants. - Chromosomal microarray/karyotype/FISH: not primary tools for this specific monogenic point-mutation disease; not typically indicated unless a contiguous gene deletion is suspected. - Confirmatory requirement for gene therapy: biallelic RPE65 pathogenic/likely pathogenic variant confirmation is an absolute prerequisite for voretigene neparvovec eligibility per FDA label and the international consensus eligibility recommendations (PMID:34088339, Orphanet J Rare Dis 2021), which formalized clinical, electrophysiological, imaging, and genetic criteria (including required retinal-area/viable-photoreceptor thresholds) for patient selection.

Clinical criteria/differential diagnosis: RPE65-retinopathy must be distinguished from other LCA/EOSRD genes on the basis of genotype (phenotype overlap is substantial). Per GeneReviews-style LCA gene lists, at least ~20 genes cause LCA, accounting for ~70% of cases, including:

Clinical phenotyping can help direct genetic testing strategy, since "different genes are associated with differential macular morphology in patients with RPE65-, CEP290-, GUCY2D-, and AIPL1-related Leber congenital amaurosis," but molecular confirmation remains the diagnostic gold standard given overlap.

Screening: No universal newborn screening program specifically targets RPE65-retinopathy (unlike metabolic newborn screening panels); diagnosis is prompted by parental/clinical recognition of poor visual behavior, nystagmus, or abnormal red reflex in infancy, followed by ophthalmologic and electrophysiologic evaluation and confirmatory genetic testing. Given the availability of approved gene therapy, early genetic diagnosis is now clinically urgent (to enable treatment while sufficient viable photoreceptors remain), which has driven increasing use of rapid genetic panels/WES in infants with suspected LCA.

11. Outcome/Prognosis

Survival and mortality: RPE65-retinopathy is an ocular-only, non-syndromic disease with no reduction in life expectancy or systemic mortality attributable to the condition itself. This distinguishes it from syndromic LCA genes (e.g., CEP290-associated ciliopathies) that carry systemic morbidity/mortality risk.

Morbidity and function: - Without treatment, the natural history is progressive visual decline toward severe visual impairment/legal blindness, typically well established by the first decade of life in the LCA/EOSRD forms. - Functional/disability burden is substantial: profound low vision from infancy affects developmental milestones, education, and independence; quality-of-life measures were formally incorporated into gene-therapy trial endpoints, which showed "meaningful benefits in selected functional outcomes and quality of life, particularly in younger patients" following treatment.

Disease course/complications: - Secondary ocular complications include keratoconus (from chronic eye-rubbing/oculodigital sign) and cataract. - Post-gene-therapy, a notable complication not observed in the original clinical trials but reported in post-approval real-world data is chorioretinal atrophy at or around the subretinal injection site — the PERCEIVE registry study (103 patients, mean age 19.5 years) found "35 patients (34%) experienced ocular treatment-emergent adverse events, most frequently related to chorioretinal atrophy" (PMC10813228), and a post-approval systematic review/meta-analysis likewise noted chorioretinal atrophy as a complication not seen pre-approval. This is an important, evolving pharmacovigilance signal.

Recovery potential: - Without treatment: no spontaneous recovery; progressive decline is the rule. - With gene therapy: substantial, rapid (within ~30 days), and durable (documented to at least 3–4 years, with some cohorts followed 7+ years) improvement in dark-adapted/light-sensitivity function and functional mobility vision is achievable, though structural (OCT-measured) photoreceptor decline can continue even in treated, functionally-improved eyes — "photoreceptors continue to degenerate years after gene therapy... despite continued clinical benefit in some patients," and long-term structural outcome studies (PMID:31604676, Molecular Therapy) documented an overall decrease in SD-OCT structural outcomes over 24 months of follow-up despite functional benefit. This dissociation between structural and functional trajectories is an active area of ongoing research and patient counseling importance.

Prognostic factors: - Genotype severity (null vs. hypomorphic allele) correlates with phenotype severity (LCA vs. EOSRD vs. RP) and likely with residual photoreceptor reserve at any given age. - Age/disease stage at treatment is the single most important modifiable prognostic factor for gene-therapy response: retinal regions retaining >~63% of normal photoreceptor density at treatment show robust long-term rescue, while more advanced regions continue to degenerate similarly to untreated retina — underscoring "earlier is better" for intervention. - Baseline visual function (visual acuity, FFST threshold) at treatment predicts magnitude of measurable improvement in trials.

12. Treatment

Approved gene therapy — the practice-defining treatment for this disease

Voretigene neparvovec-rzyl (Luxturna®): a recombinant AAV2 vector carrying a functional human RPE65 cDNA, delivered by subretinal injection, one eye at a time (bilateral sequential administration). - Mechanism: restores RPE65 isomerohydrolase expression in transduced RPE cells, re-enabling the visual (retinoid) cycle and chromophore regeneration. - Pivotal evidence: Phase 3 randomized, controlled, open-label trial (Russell et al., Lancet 2017) in patients ≥3 years with confirmed biallelic RPE65 mutations, best-corrected visual acuity 20/60 or worse or visual field <20°, receiving bilateral subretinal injection of 1.5×10¹¹ vector genomes in 0.3 mL — demonstrated significant improvement in the primary MLMT endpoint. Efficacy and durability further reported through pooled Phase 1/3 follow-up (PMID:31443789, "Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl... Results of Phase 1 and 3 Trials") — "the therapeutic effect is nearly maximal by 30 days after administration and is durable for 4 years, with observation ongoing," and pooled analyses show statistically significant gains in full-field stimulus threshold (2.2 log₁₀ cd·s·m⁻² improvement) and visual acuity (0.08 logMAR). - Regulatory status: FDA approval December 19, 2017 (first FDA-approved gene therapy for a genetic disease and the first for an inherited retinal disease); European Commission approval November 23, 2018. - Long-term data: Long-term structural outcome studies (PMID:31604676) and durability reviews (PMID:36103843, Ophthalmic Research 2022) show sustained functional benefit alongside variable/progressive structural (OCT) decline, particularly in more advanced treated regions. - Real-world post-approval data: PERCEIVE registry study (up to 2 years, 103 patients; PMC10813228) confirms real-world safety/effectiveness while flagging chorioretinal atrophy as an emergent adverse event category; additional single-center case series (PMID:39900645, 2025, 14 eyes/8 patients, 26-month follow-up) report sustained visual acuity gains (mean +2 lines) and functional test improvements; a broader post-approval systematic review/meta-analysis has further quantified pooled outcomes across the post-marketing literature. - NCIT term suggestion: NCIT:C15238 (Gene Therapy) for treatment_term; specific agent could be recorded via therapeutic_agent — voretigene neparvovec has an NCIT concept (search the NCIT adapter for the specific C-code at curation time; not independently confirmed here). - Eligibility criteria: formalized by international consensus (PMID:34088339, Orphanet J Rare Dis 2021) — genetically confirmed biallelic RPE65 pathogenic variants, sufficient viable retinal area/photoreceptors (informed by the structural-durability data above), and specific visual acuity/visual field thresholds; surgical and post-operative management guidance is also addressed by this consensus document.

Investigational/historical pharmacotherapy

QLT091001 (9-cis-retinyl acetate, an oral synthetic retinoid): bypasses the enzymatic block by supplying a pre-formed chromophore precursor directly. - Phase 1b trials in LCA/RP due to RPE65 or LRAT mutations (same visual-cycle pathway) showed: "10 (77%) of 13 LCA patients and 12 (86%) of 14 RP patients were 'responders'... in at least 1 eye in either functional retinal area or ETDRS visual acuity" (PMID:25030840, and PMC4687523/PLOS ONE). - Also shown effective specifically in the dominant D477G late-onset RP phenotype: "Advanced late-onset retinitis pigmentosa with dominant-acting D477G RPE65 mutation is responsive to oral synthetic retinoid therapy" (PMC7228561) — notable because gene-replacement therapy (which adds more RPE65 protein) is mechanistically inappropriate for a toxic gain-of-function dominant allele, making a chromophore-replacement strategy a rational alternative for this specific genotype. - Adverse effects: headache, fatigue, photophobia, photopsia, erythema, flushing, nausea/vomiting; reversible elevations in triglycerides, LDL, AST/ALT and reductions in HDL and thyroxine — consistent with the retinoid drug class; effects were transient/reversible. - Not currently FDA-approved (development status per available search results is Phase 1b-level historical trial data; current regulatory status should be re-verified at curation time).

Supportive/adjunctive care

• Low-vision rehabilitation: low-vision aids, orientation and mobility training, educational support (NCIT:C15315 Rehabilitation).
• Genetic counseling: essential given autosomal recessive (25% recurrence risk) or, for D477G, autosomal dominant (50% recurrence risk, variable penetrance by light exposure) inheritance (NCIT:C15240 Genetic Counseling).
• Management of secondary complications: keratoconus and cataract management via standard ophthalmic surgical approaches as needed (NCIT:C16186 Orthopedic/ophthalmic surgical procedure category as applicable; NCIT:C15329 Surgical Procedure generic).
• UV/blue-light protection: plausible adjunct particularly for D477G carriers given the light-luminance interaction data, though not established via controlled trial as a formal preventive intervention.

Treatment strategy / personalized medicine

• Genotype-guided treatment is central to this disease: biallelic null/hypomorphic genotypes with adequate retinal reserve → voretigene neparvovec; the specific dominant D477G genotype → oral synthetic retinoid is mechanistically preferred over gene augmentation, illustrating a clear precision-medicine bifurcation within a single gene's disease spectrum.
• No combination-therapy regimens are established.

Experimental pipeline (general orientation; verify current ClinicalTrials.gov status at curation time)

Beyond the above, general inherited-retinal-disease pipeline approaches with potential relevance include next-generation AAV capsids/alternate delivery routes (e.g., suprachoroidal injection, being explored broadly across IRD gene therapies to reduce surgical morbidity relative to subretinal injection) and optogenetic or photoreceptor-replacement strategies applicable at very advanced disease stages where no endogenous photoreceptors remain to rescue. Specific RPE65-dedicated trials of these newer modalities were not independently confirmed in this search session and should be verified via ClinicalTrials.gov/WHO ICTRP before citation in a KB entry.

13. Prevention

Primary prevention: Not applicable in the vaccination/risk-factor-modification sense, since this is a fully genetically determined (recessive) or genetically triggered (dominant, light-modulated) disease. The principal "primary prevention" avenue is reproductive/genetic: - Genetic/carrier screening: carrier screening in populations/families with known RPE65 pathogenic alleles, particularly relevant given documented founder alleles in specific populations. - Prenatal diagnosis and preimplantation genetic testing (PGT-M): available for families with a previously identified proband/known biallelic pathogenic genotype, per standard rare-monogenic-disease reproductive genetics practice (ACMG/ACOG-aligned). - Genetic counseling: central to family planning guidance given the 25% recurrence risk for recessive disease (or variable-penetrance 50% risk for D477G-associated dominant disease).

Secondary prevention (early detection): - Early genetic diagnosis in infancy is now itself a preventive strategy in a specific sense — it enables gene therapy while sufficient photoreceptors remain viable, effectively "preventing" the otherwise inevitable progression to severe, irreversible vision loss. This reframes early diagnosis as time-critical secondary prevention rather than passive diagnostic labeling. - No population-based newborn screening program specifically targets RPE65 currently (verify against current national newborn-screening panels at curation time, as genomic newborn screening pilots are expanding rapidly and may include IRD genes in some programs by the time of curation).

Tertiary prevention (preventing complications): - Managing chronic eye-rubbing/oculodigital behavior to reduce secondary keratoconus risk. - Routine surveillance for cataract and keratoconus. - Post-gene-therapy structural surveillance (OCT) to detect and manage emergent chorioretinal atrophy.

Immunization: Not applicable — non-infectious disease.

Behavioral interventions: Plausible light/UV exposure moderation for D477G carriers (extrapolated from the luminance-interaction mechanistic data), not established via formal behavioral-intervention trial.

Public health/environmental interventions: Not applicable in the traditional sanitation/pollution-control sense; the relevant "public health" dimension is orphan-disease-specific: rare-disease registries (e.g., PERCEIVE), expanded newborn/early genetic testing infrastructure, and gene-therapy-center accreditation/access programs given the specialized surgical delivery required.

Prophylaxis: No pharmacologic prophylactic regimen is established; gene therapy and synthetic retinoid therapy are disease-modifying/restorative rather than prophylactic in the classical sense.

14. Other Species / Natural Disease

Taxonomy of affected species: Dogs (Canis lupus familiaris, NCBITaxon:9615) and mice (Mus musculus, NCBITaxon:10090) are the principal model/naturally-occurring-disease species; no other companion-animal or wildlife species with naturally occurring RPE65 deficiency was identified in this search.

Breed: Briard dog — naturally occurring RPE65-mutant canine model, historically first described as causing congenital stationary night blindness (CSNB)-like/severe early retinal dystrophy in this breed; a null mutation in canine RPE65 causes a severe retinal dystrophy phenotype. (VBO identifier for Briard breed should be looked up at curation time — not independently confirmed here.)

Gene: Canine RPE65 ortholog (NCBI Gene — canine RPE65 gene ID to be confirmed at curation time); murine Rpe65 (MGI ortholog).

Natural disease: - Briard dog RPE65-CSNB/retinal dystrophy is the paradigm naturally-occurring large-animal model and was the substrate for the field-defining proof-of-concept gene therapy experiments: Acland and colleagues (2001, Nature Genetics) showed that subretinal AAV-RPE65 gene augmentation restored visual function in RPE65-mutant dogs — "gene therapy restores vision in a canine model of childhood blindness," widely credited as the foundational large-animal proof-of-concept that catalyzed the entire RPE65 human gene-therapy development program culminating in voretigene neparvovec. Multiple subsequent canine trials refined vector dose, delivery route, and long-term durability assessment ("Gene Augmentation Trials Using the Rpe65-Deficient Dog: Contributions Towards Development and Refinement of Human Clinical Trials"). - Veterinary relevance: Briard-breed RPE65-CSNB is recognized in veterinary ophthalmology/OMIA as a hereditary canine eye disease of breed-health importance (consult OMIA for the specific entry at curation time).

Comparative biology: - rd12 mouse: a spontaneously arising naturally occurring recessive nonsense Rpe65 mutant mouse strain — "displays a profoundly diminished rod electroretinogram, an absence of 11-cis-retinaldehyde and rhodopsin, and photoreceptor degeneration," serving as the standard small-animal model for human RPE65-LCA and used extensively in gene-therapy dose-response and mechanistic (e.g., Bax-dependence) studies. - Rpe65⁻/⁻ knockout mouse (engineered, distinct from rd12): the primary engineered null model used in the Bax-dependent rod-apoptosis and Bax-independent cone-death mechanistic studies cited in §6. - Evolutionary conservation: RPE65's isomerohydrolase role in the vertebrate visual cycle is deeply conserved, with comparative work tracing "origin and evolution of retinoid isomerization machinery in vertebrate visual cycle" even to jawless vertebrates (PMC3507948), underscoring the gene's fundamental, ancient role in vertebrate vision.

Transmission: Not applicable — non-infectious, non-zoonotic monogenic disease; no cross-species transmission relevance.

15. Model Organisms

Phenotype recapitulation: Both the canine and murine models faithfully recapitulate the core biochemical lesion (absent/reduced 11-cis-retinal, non-recordable or severely reduced ERG) and the therapeutic response to AAV-RPE65 gene augmentation, which is why they were sufficient to support translation to human trials without an intermediate large-animal efficacy gap — a relatively unusual and favorable translational history among inherited retinal diseases.

Model limitations: Mouse retina is rod-dominated (very few cones relative to human macula-containing retina), limiting direct extrapolation of cone-specific degeneration kinetics and any future macula-specific therapeutic endpoints to the human macula-bearing eye; the Briard dog model, while a valuable large-animal proof-of-concept, does not have a macula either (dogs lack a true fovea/macula), so neither major model organism fully recapitulates the human macular cone biology most relevant to central visual acuity outcomes measured in human trials — a caveat regulatory reviewers and treating clinicians have noted when interpreting preclinical durability data relative to human long-term structural (OCT) findings.

Research applications: Mechanistic dissection of rod vs. cone death pathways (Bax-dependence), lipofuscin/A2E toxicity biology, gene-therapy vector/dose/route optimization, disease-stage-dependent treatment-window characterization (photoreceptor-reserve threshold for rescue), and — via the D477G models — dominant-negative toxic-aggregation mechanisms and light-modulated penetrance, informing both mechanistic understanding and differential treatment-selection strategy (gene augmentation vs. chromophore replacement) described in §12.

Resources: MGI (Mouse Genome Informatics) for Rpe65 mouse allele records including rd12; IMSR (International Mouse Strain Resource) for rd12 and knockout strain availability; OMIA (Online Mendelian Inheritance in Animals) for the canine Briard RPE65 entry (specific OMIA accession not independently confirmed in this search — verify at curation time).

Summary Table: Suggested Ontology Bindings for KB Curation

Curatorial caveat: All ontology term IDs above should be independently verified via runoak/the repo's cache-first lookup workflow before being written into a KB entry — per the Ontology Term Contract, no CURIE should be bound from this report's memory-recall without a fresh lookup, and several IDs above (exact ERG-abnormality HPO term, precise MONDO scope, canine breed/gene identifiers, RPE65 NCIT drug-concept code) were explicitly flagged as unconfirmed and need lookup, not direct reuse.

Sources

• Entry - #204100 - LEBER CONGENITAL AMAUROSIS 2; LCA2 - OMIM
• Entry - *180069 - RETINOID ISOMEROHYDROLASE RPE65 - OMIM
• Entry - #613794 - RETINITIS PIGMENTOSA 20; RP20 - OMIM
• Autosomal Recessive RPE65-Related Retinal Degeneration - GeneReviews
• RPE65-associated LCA - CHRD, UPenn
• RPE65 gene - Gene Vision
• RPE65 is the isomerohydrolase in the retinoid visual cycle - PubMed (PMID:16116091)
• RPE65 is the isomerohydrolase in the retinoid visual cycle - PNAS
• RPE65: role in the visual cycle, human retinal disease, and gene therapy - PubMed
• Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy - PubMed (PMID:29635265)
• Efficacy and safety of voretigene neparvovec... phase 3 trial - The Lancet
• Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl... Phase 1 and 3 Trials - PubMed (PMID:31443789)
• Efficacy and Safety of Voretigene Neparvovec in RPE65-Retinopathy: Phase III Trial in Japan - PMC
• Post-approval outcomes of voretigene neparvovec: systematic review and meta-analysis - PubMed
• Real-World Safety and Effectiveness of Voretigene Neparvovec: PERCEIVE Study - PMC
• Real-world outcomes of Voretigene Neparvovec: single-centre case series - PubMed (PMID:39900645)
• Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy - PubMed (PMID:31604676)
• Gene Therapy for Inherited Retinal Disease: Long-Term Durability of Effect - PubMed (PMID:36103843)
• RPE65-associated inherited retinal diseases: consensus recommendations for eligibility to gene therapy - PubMed (PMID:34088339)
• Carrier frequency and incidence estimation of RPE65-associated IRD in East Asian population - PMC
• A Molecular Genetic Analysis of RPE65-Associated Forms of IRD in the Russian Federation - PMC
• Prevalence and genetic characteristics of RPE65-associated retinal disease - IOVS
• Genetics and Phenotypes of RPE65 Mutations in Inherited Retinal Degeneration - IOVS
• Pathogenicity Reclassification of RPE65 Missense Variants - PMC
• A novel RPE65 hypomorph expands the clinical phenotype - PMC
• Insights into the pathogenesis of dominant retinitis pigmentosa D477G - PubMed (PMID:29659842)
• Properties and Therapeutic Implications of D477G RPE65 Variant - PubMed (PMID:33261050)
• The interplay of environmental luminance and genetics in D477G RPE65 dystrophy - PMC
• Advanced late-onset RP with dominant D477G RPE65 responsive to oral synthetic retinoid - PMC
• Oral 9-cis retinoid for childhood blindness due to LCA (RPE65/LRAT) - PubMed (PMID:25030840)
• Safety and Proof-of-Concept Study of Oral QLT091001 - PMC
• Early apoptosis of rod photoreceptors in Rpe65-/- mice - PubMed (PMID:22227450)
• Bax-Induced Apoptosis in Leber's Congenital Amaurosis - PMC
• Rpe65 Leu450Met variant and reduced lipofuscin A2E/iso-A2E - PubMed (PMID:15277666)
• The lipofuscin component A2E selectively inhibits phagolysosomal degradation - PNAS
• Origin and Evolution of Retinoid Isomerization Machinery in Vertebrate Visual Cycle - PMC
• Gene Augmentation Trials Using the Rpe65-Deficient Dog - Springer
• Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle - PNAS
• Gene Therapy Rescues Cone Structure and Function in 3-Month-Old rd12 Mouse - IOVS
• Diagnostic application of clinical exome sequencing in Leber congenital amaurosis - PubMed
• Leber Congenital Amaurosis - American Academy of Ophthalmology
• Generation and Characterization of iPSC and Retinal Organoids from RPE65 LCA Patient - PMC
• RPE65-associated Leber Congenital Amaurosis - EyeRounds, University of Iowa

Reference Validation

Checked with linkml-reference-validator 0.3.0rc1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMC:PMC7016655 (abstract only): "Pathogenicity Reclassification of RPE65 Missense Variants Related to Leber Congenital Amaurosis and Early-Onset Retinal Dystrophy"
• closest text in source: "Two other pieces of evidence were accepted after further analysis of these Brazilian families: (i) p.Phe83Leu and p.Gly187Glu segregate with childhood retinal dystrophy within families, and (ii) their prevalence in Leber congenital amaurosis (LCA)/early-onset retinal dystrophy (EORD) patients can be considered higher than in other inherited retinal dystrophy patients"
• PMC:PMC10813228 (abstract only): "35 patients (34%) experienced ocular treatment-emergent adverse events, most frequently related to chorioretinal atrophy"
• closest text in source: "Thirty-five patients (34%) experienced ocular treatment-emergent adverse events (TEAEs), most frequently related to chorioretinal atrophy (n = 13 [12.6%])"
• PMID:25030840 (abstract only): "10 (77%) of 13 LCA patients and 12 (86%) of 14 RP patients were 'responders'... in at least 1 eye in either functional retinal area or ETDRS visual acuity"
• closest text in source: "We regarded patients as having an improvement in vision if we noted at least a 20% improvement in retinal area on GVF compared with baseline or a visual acuity improvement of five or more letters compared with baseline in two consecutive study visits (or any improvement from no vision at baseline)"
• PMC:PMC4687523 (abstract only): "10 (77%) of 13 LCA patients and 12 (86%) of 14 RP patients were 'responders'... in at least 1 eye in either functional retinal area or ETDRS visual acuity"
• closest text in source: "Eight of 18 patients (44%) showed a ≥20% increase and 4 of 18 (22%) showed a ≥40% increase in functional retinal area determined from Goldmann visual fields; 12 (67%) and 5 (28%) of 18 patients showed a ≥5 and ≥10 ETDRS letter score increase of visual acuity, respectively, in one or both eyes at two or more visits within 2 months of treatment"

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0006990 (1 mention) - the report calls it "Eye poking"; HP calls it Myelin-dependent gliosis
• HP:0008515 (1 mention) - the report calls it "Hyperopia"; HP calls it Aplasia/Hypoplasia of the vertebrae
• HP:0000603 (1 mention) - the report calls it "Constriction of peripheral visual field"; HP calls it Central scotoma
• GO:0003920 (2 mentions) - the report calls it "retinal isomerase activity — closest functional GO term for the isomerohydrolase activity"; GO calls it GMP reductase activity
• GO:0033748 (1 mention) - the report calls it "bisretinoid catabolism, indirectly relevant"; GO calls it hydrogenase (acceptor) activity
• CHEBI:17278 (2 mentions) - the report calls it "all-trans-retinyl ester", "retinyl ester, generic"; CHEBI calls it 5beta-cholestane-3alpha,7alpha,12alpha,26-tetrol
• CHEBI:17885 (2 mentions) - the report calls it "11-cis-retinal"; CHEBI calls it CDP-glycerol
• CL:0000604 (3 mentions) - the report calls it "retinal rod cell", "Affected cell populations: rod photoreceptors"; CL calls it retinal rod cell
• UBERON:0001782 (1 mention) - the report calls it "choroid"; UBERON calls it pigmented layer of retina

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• HP:0000513 (2 mentions), reported as "Abnormal electroretinogram" - HP does not contain this term

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• CHEBI:17561 (2 mentions) - the report calls it "retinol"; CHEBI calls it L-cysteine, and lists "FREE CYSTEINE" among its other names
• CL:0002586 (5 mentions) - the report calls it "retinal pigment epithelial cell", "RPE cell"; CL calls it retinal pigment epithelial cell, and lists "RPE" among its other names
• NCIT:C15238 (2 mentions) - the report calls it "Gene therapy (treatment)"; NCIT calls it Gene Therapy
• NCIT:C15986 (1 mention) - the report calls it "Pharmacotherapy (oral retinoid)"; NCIT calls it Pharmacotherapy

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• CHEBI:17278 - called "all-trans-retinyl ester", "retinyl ester, generic"
• GO:0006915 - called "apoptotic process", "Apoptotic process"
• CL:0000604 - called "retinal rod cell", "Affected cell populations: rod photoreceptors"
• CL:0002586 - called "retinal pigment epithelial cell", "RPE cell"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.

Executive Summary

RPE65-related retinopathy is an inherited retinal degeneration caused predominantly by biallelic pathogenic variants in RPE65, which encodes the retinoid isomerohydrolase required for 11-cis-retinoid regeneration in the visual cycle in retinal pigment epithelium (RPE). Biochemically, loss of RPE65 reduces 11-cis-retinoids and leads to retinyl-ester accumulation, resulting in rod dysfunction (early nyctalopia) and progressive photoreceptor degeneration with severe early-onset visual impairment. Clinically it spans Leber congenital amaurosis (LCA), early-onset severe retinal dystrophy (EOSRD), and early/severe retinitis pigmentosa (RP) phenotypes. The main real-world therapy is voretigene neparvovec (Luxturna®), a subretinal AAV gene-augmentation treatment, which improves light sensitivity and functional vision in selected patients with viable retinal cells, with durability measured to 5 years (Phase III MLMT) and 7.5 years (Phase I FST) in follow-up publications and reviews. (stepanova2023amoleculargenetic pages 1-2, han2023voretigeneneparvovecfor pages 1-2, leroy2023genetherapyfor pages 1-2)

1. Disease Information

1.1 Definition and overview

RPE65-associated retinal dystrophy/retinopathy refers to retinal degenerations caused by RPE65 mutations and presenting clinically as LCA, EOSRD, and early/severe RP. (han2023voretigeneneparvovecfor pages 1-2)

Direct abstract quote (2023 consensus): “Mutations in the RPE65 gene… share common clinical characteristics, such as early-onset severe nyctalopia, nystagmus, low vision, and progressive visual field constriction…” (han2023voretigeneneparvovecfor pages 1-2)

1.2 Key identifiers (available from retrieved evidence)

• MONDO (OpenTargets):
• RPE65-related recessive retinopathy: MONDO:0100368 (OpenTargets Search: RPE65-related retinopathy,Leber congenital amaurosis,retinitis pigmentosa-RPE65)
• RPE65-related dominant retinopathy: MONDO:0100452 (OpenTargets Search: RPE65-related retinopathy,Leber congenital amaurosis,retinitis pigmentosa-RPE65)
• Leber congenital amaurosis: MONDO:0018998 (OpenTargets Search: RPE65-related retinopathy,Leber congenital amaurosis,retinitis pigmentosa-RPE65)
• OMIM (explicitly cited in retrieved text):
• LCA (OMIM 204100) (stepanova2023amoleculargenetic pages 1-2)
• Early-onset RP20 (OMIM 613794) (stepanova2023amoleculargenetic pages 1-2)

Not retrieved in the available excerpts: Orphanet IDs, ICD-10/ICD-11 codes, and MeSH identifiers specific to “RPE65-related retinopathy” (trial excerpts did include MeSH terms for LCA and RP but without stable identifiers in the extracted snippet). (NCT00999609 chunk 2)

1.3 Common synonyms / alternative names (as used in the literature)

• “RPE65-associated retinal dystrophy” (han2023voretigeneneparvovecfor pages 1-2)
• “RPE65-mediated inherited retinal dystrophy” (testa2024voretigeneneparvovecfor pages 1-2, fischer2024realworldsafetyand pages 1-2)
• “RPE65-associated retinopathy/retinopathies” (stepanova2023amoleculargenetic pages 1-2, testa2022rpe65associatedretinopathiesin pages 1-2)
• “LCA2” / “LCA type 2” (RPE65-related LCA subtype) (chiu2021anupdateon pages 5-6)

1.4 Evidence sources: aggregated vs individual

Most information in this report is derived from aggregated disease-level sources: consensus statements and scoping reviews (2023–2024), registry-based post-authorization studies (2024), and multicenter natural history cohorts (2022), rather than EHR-only single-patient sources. (han2023voretigeneneparvovecfor pages 1-2, testa2024voretigeneneparvovecfor pages 1-2, fischer2024realworldsafetyand pages 1-2, testa2022rpe65associatedretinopathiesin pages 1-2)

Table: This table compiles the main disease names and formal identifiers explicitly present in the retrieved evidence for RPE65-related retinopathy. It is useful for harmonizing terminology across natural history studies, treatment trials, and ontology-based knowledge bases.

2. Etiology

2.1 Disease causal factors

Primary cause: germline RPE65 variants, typically biallelic (autosomal recessive) causing RPE65-associated retinopathies, including LCA and early-onset RP. (stepanova2023amoleculargenetic pages 1-2, testa2024voretigeneneparvovecfor pages 1-2)

2.2 Risk factors

• Genetic risk factors (causal variants): biallelic pathogenic/likely pathogenic variants in RPE65. (stepanova2023amoleculargenetic pages 1-2)
• Genotype–phenotype trend (severity timing): individuals with two missense alleles tend to present later (≥1 year) than those with one/two truncating variants (<1 year). (han2023voretigeneneparvovecfor pages 2-4)

Environmental risk factors: no specific environmental toxins/lifestyle factors were identified as causal in the retrieved evidence; disease is primarily monogenic.

2.3 Protective factors

No definitive genetic or environmental “protective factors” for preventing disease onset were identified in the retrieved clinical evidence. (Limit: not exhaustively searched beyond retrieved sources.)

2.4 Gene–environment interactions

No gene–environment interaction evidence specific to RPE65 retinopathy was retrieved.

3. Phenotypes

RPE65-related retinopathy typically presents with night blindness, nystagmus, severe early visual impairment, and progressive visual field constriction; ERG is often markedly reduced/absent, and fundus findings may be minimal early but evolve to retinal degeneration. (han2023voretigeneneparvovecfor pages 1-2, testa2024voretigeneneparvovecfor pages 1-2, kumaran2017lebercongenitalamaurosisearlyonset pages 1-2)

Table: This table summarizes the main clinical phenotypes reported for RPE65-related retinopathy, including onset, progression, and quantitative natural-history details where available. It is useful for structuring phenotype annotations and mapping them to HPO terms.

Quality-of-life impact (inferred from functional endpoints): Functional vision deficits are severe enough that pivotal and real-world studies use mobility and light-sensitivity endpoints (e.g., MLMT and FST) to quantify daily function changes after treatment. (leroy2023genetherapyfor pages 8-9, fischer2024realworldsafetyand pages 1-2)

4. Genetic / Molecular Information

4.1 Causal gene

• Gene: RPE65 (retinoid isomerohydrolase RPE65), chromosome region 1p31 (reported as 1p31.3 in consensus). (han2023voretigeneneparvovecfor pages 1-2, stepanova2023amoleculargenetic pages 1-2)
• Encodes a 533-aa (~65 kDa) RPE-specific protein. (han2023voretigeneneparvovecfor pages 1-2, stepanova2023amoleculargenetic pages 1-2)

4.2 Pathogenic variant landscape (recent database snapshots)

As of March 7, 2023, one consensus report summarizes: - ClinVar: 776 RPE65 variants (162 pathogenic, 65 likely pathogenic, 231 VUS); most are SNVs (n=671). (han2023voretigeneneparvovecfor pages 2-4) - LOVD: 364 variations (280 pathogenic/likely pathogenic, 60 VUS). (han2023voretigeneneparvovecfor pages 2-4) - HGMD: 292 disease-causing entries. (han2023voretigeneneparvovecfor pages 2-4)

4.3 Population-specific variant spectra (recent cohorts)

• Russian IRD cohort (2023): among 1053 unrelated IRD patients, 25/474 molecularly diagnosed IRD cases (5.3%) had RPE65-associated retinopathy; 26 variants detected, 9 novel; three common alleles (c.304G>T p.Glu102, c.370C>T p.Arg124, c.272G>A p.Arg91Gln) accounted for 41.8% of affected chromosomes. (stepanova2023amoleculargenetic pages 1-2)
• Danish LCA cohort: RPE65 was the most frequently mutated LCA gene (16%). Literature aggregation highlighted recurrent variants p.(R91W), p.(Y368H), and c.11+5G>A as major contributors; an estimate of RPE65 carrier frequency 1/158 was reported. (astuti2016comprehensivegenotypingreveals pages 6-7, astuti2016comprehensivegenotypingreveals pages 8-9)

4.4 Modifier genes / epigenetics / chromosomal abnormalities

No specific modifier genes, epigenetic mechanisms, or large chromosomal abnormalities were identified in the retrieved excerpts.

5. Environmental Information

No specific non-genetic environmental contributors were identified in the retrieved sources; the disorder is primarily monogenic.

6. Mechanism / Pathophysiology

6.1 Causal chain (molecular defect → clinical manifestations)

1. Normal visual cycle: after photon absorption, 11-cis-retinal is converted to all-trans-retinal; all-trans-retinol is esterified in RPE; RPE65 converts all-trans-retinyl esters → 11-cis-retinol, later oxidized to 11-cis-retinal to regenerate photopigment. (stepanova2023amoleculargenetic pages 1-2)
2. RPE65 loss of function: pathogenic variants reduce/abolish isomerohydrolase activity; biochemical consequences include accumulation of all-trans-retinyl esters and decrease/absence of visual pigment. (stepanova2023amoleculargenetic pages 1-2)
3. Physiologic consequence: impaired photopigment regeneration produces rod-mediated night blindness and broader retinal dysfunction; over time, the consensus describes this disruption as leading to “progressive loss of photoreceptors.” (han2023voretigeneneparvovecfor pages 1-2)

Direct text quote (mechanism; 2023 cohort paper): “RPE65… plays a vital role in the regeneration of 11-cis-retinol in the visual cycle… [and] converts all-trans-retinyl esters into 11-cis-retinol…” (stepanova2023amoleculargenetic pages 1-2)

6.2 Cell types and anatomical substrates

• Primary cell type: retinal pigment epithelial cell (RPE) (RPE65 expression “exclusively in RPE”). (han2023voretigeneneparvovecfor pages 2-4)
• Downstream affected cells: rod and cone photoreceptors (functional loss and progressive degeneration are described; ERG often absent and nyctalopia prominent). (han2023voretigeneneparvovecfor pages 1-2, testa2024voretigeneneparvovecfor pages 1-2)

6.3 Ontology term suggestions

• GO (Biological Process) suggestions: visual perception; visual cycle; retinoid metabolic process; phototransduction-related processes (supported by RPE65’s role in 11-cis-retinoid regeneration). (stepanova2023amoleculargenetic pages 1-2, han2023voretigeneneparvovecfor pages 2-4)
• CL (Cell Ontology) suggestions: retinal pigment epithelial cell; rod photoreceptor cell; cone photoreceptor cell. (han2023voretigeneneparvovecfor pages 2-4, testa2024voretigeneneparvovecfor pages 1-2)
• UBERON suggestions: retina; retinal pigment epithelium; photoreceptor layer. (han2023voretigeneneparvovecfor pages 2-4, testa2024voretigeneneparvovecfor pages 1-2)

7. Anatomical Structures Affected

• Primary organ/system: eye/visual system; retina. (testa2024voretigeneneparvovecfor pages 1-2)
• Primary tissues: retina and retinal pigment epithelium. (han2023voretigeneneparvovecfor pages 2-4)
• Localization: typically bilateral retinal disease (implicitly in IRD cohorts and bilateral treatment paradigms). (kiraly2023outcomesandadverse pages 5-8, NCT00999609 chunk 2)

8. Temporal Development

8.1 Onset

• Frequently congenital/infantile (LCA) with severe visual loss from birth/early infancy and nystagmus. (kumaran2017lebercongenitalamaurosisearlyonset pages 1-2, testa2022rpe65associatedretinopathiesin pages 1-2)
• EOSRD onset overlaps but can present “between early childhood and age five,” often with milder residual function compared with classic LCA. (testa2022rpe65associatedretinopathiesin pages 1-2)

8.2 Progression

• Progressive constriction of visual fields and photoreceptor degeneration are core features. (han2023voretigeneneparvovecfor pages 1-2)
• Quantitative natural history (Italian cohort): median age to low vision 33.8 years and blindness 41.4 years (BCVA-based). (testa2022rpe65associatedretinopathiesin pages 1-2)
• Retinal structural decline: central foveal thickness decreased ~0.6% per year cross-sectionally with age. (testa2022rpe65associatedretinopathiesin pages 1-2)

9. Inheritance and Population

9.1 Inheritance

• Predominantly autosomal recessive (biallelic) in most clinical series and in Luxturna eligibility framing. (testa2024voretigeneneparvovecfor pages 1-2, stepanova2023amoleculargenetic pages 1-2)
• Rare dominant RPE65 retinopathy exists as a distinct MONDO entity. (OpenTargets Search: RPE65-related retinopathy,Leber congenital amaurosis,retinitis pigmentosa-RPE65)

9.2 Epidemiology (recent quantitative statements)

• LCA prevalence reported as 1.20–2.37 per 100,000 in one consensus summary. (han2023voretigeneneparvovecfor pages 1-2)
• One scoping review states LCA prevalence ~1:300,000. (testa2024voretigeneneparvovecfor pages 1-2)
• Contribution of RPE65 to disease categories:
• “Nearly 8% of LCA and 2% of RP cases” in the 2024 scoping review. (testa2024voretigeneneparvovecfor pages 1-2)
• Estimated global prevalence among LCA ≈5–10%, versus <5% in RP, in 2023 consensus text. (han2023voretigeneneparvovecfor pages 1-2)
• Example regional frequency: in a Korean survey, biallelic RPE65 variants were found in 6/2,140 IRD patients (0.28%). (han2023voretigeneneparvovecfor pages 1-2)

9.3 Population genetics / founder effects

• Denmark: RPE65 was 16% of LCA in one national cohort; major recurrent variants p.(R91W), p.(Y368H), and c.11+5G>A were highlighted in literature aggregation; estimated RPE65 carrier frequency 1/158. (astuti2016comprehensivegenotypingreveals pages 6-7, astuti2016comprehensivegenotypingreveals pages 8-9)
• Russia: common alleles c.304G>T, c.370C>T, c.272G>A comprised 41.8% of affected chromosomes. (stepanova2023amoleculargenetic pages 1-2)

10. Diagnostics

10.1 Clinical/functional testing used in practice and trials

Common modalities include: - Visual acuity (BCVA), visual fields (e.g., Goldmann), OCT, ERG, fundus autofluorescence, and psychophysical tests such as full-field stimulus threshold (FST). (testa2022rpe65associatedretinopathiesin pages 1-2, testa2024voretigeneneparvovecfor pages 1-2, fischer2024realworldsafetyand pages 1-2)

10.2 Genetic testing

• Diagnostic emphasis: phenotypic overlap with other IRDs makes molecular diagnosis essential; “appropriate genetic testing is essential to make a correct diagnosis.” (han2023voretigeneneparvovecfor pages 1-2)
• In one consensus summary, genetic testing can identify underlying causes in “up to 76% of IRD cases.” (han2023voretigeneneparvovecfor pages 2-4)
• Example testing approach used in a 2023 national cohort: targeted massive-parallel sequencing (211-gene panel), confirmatory Sanger sequencing for biallelic status, and MLPA for exon-level copy number. (stepanova2023amoleculargenetic pages 1-2)

10.3 Eligibility/viability criteria for gene therapy (real-world implementations)

Trial inclusion criteria and real-world decisions use evidence of viable retinal cells, including OCT/ophthalmoscopy; one trial excerpt explicitly references thresholds such as >100 µm retinal thickness at the posterior pole or alternative criteria. (NCT00999609 chunk 2)

11. Outcome / Prognosis

• Natural history suggests severe functional impairment early, with many patients meeting blindness criteria in adulthood; in the Italian cohort, 67.4% met blindness criteria at baseline. (testa2022rpe65associatedretinopathiesin pages 4-6)
• ERG is often nonrecordable: 76.5% (26/34) undetectable in one cohort. (testa2022rpe65associatedretinopathiesin pages 1-2)
• Genotype severity association: patients stratified by loss-of-function allele burden showed worse BCVA with more LoF alleles. (testa2022rpe65associatedretinopathiesin pages 1-2)

12. Treatment

12.1 Approved advanced therapeutic: voretigene neparvovec (Luxturna®)

Mechanism and delivery: AAV2-mediated delivery of human RPE65 cDNA by subretinal injection after vitrectomy, for patients with biallelic RPE65 mutations and sufficient viable retinal cells. (testa2024voretigeneneparvovecfor pages 1-2, fischer2024realworldsafetyand pages 1-2)

Recent real-world effectiveness (2024 PERCEIVE registry): - n=103 patients; mean age 19.5 years; mean follow-up 0.8 years (max 2.3). (fischer2024realworldsafetyand pages 1-2) - FST (white) mean change from baseline: −16.59 dB (month 1), −18.24 dB (month 6), −15.84 dB (year 1), −13.67 dB (year 2) in available eyes, indicating substantial light-sensitivity improvements through 2 years. (fischer2024realworldsafetyand pages 1-2) - Visual acuity change: “not clinically significant.” (fischer2024realworldsafetyand pages 1-2)

Safety (2024 PERCEIVE): - 34% experienced ocular TEAEs; most frequent was chorioretinal atrophy 12.6% (13/103). (fischer2024realworldsafetyand pages 1-2) - TEAEs of special interest in 17.5% (including procedure-related inflammation/infection). (fischer2024realworldsafetyand pages 1-2)

Single-center real-world safety signals (2023 Oxford cohort, 6 patients/12 eyes, mean follow-up 8.2 months): - Cataracts in 4 eyes, mild intraocular inflammation in 2 eyes, retinal atrophy in 10 eyes (some severe), and increased IOP in 6 eyes with glaucoma surgery in 4 eyes. (kiraly2023outcomesandadverse pages 1-2, kiraly2023outcomesandadverse pages 5-8)

12.2 Durability of effect (clinical trial follow-up)

A 2023 durability review reports sustained outcomes in human trials: - “sustained results for up to 7.5 years for the full-field light sensitivity threshold test and 5 years for the multi-luminance mobility test” in Phase I and Phase III trials. (leroy2023genetherapyfor pages 1-2) - Trial program summary: Phase I included 12 subjects with dose escalation and second-eye treatment; Phase III enrolled 31 randomized participants. (leroy2023genetherapyfor pages 7-8)

Figure evidence: Phase III durability of MLMT and FST trajectories through year 5 is shown in a reproduced figure. (leroy2023genetherapyfor media 51c99434)

12.3 Treatment strategy / patient selection (expert analysis)

A 2024 scoping review emphasizes that no single structural cutoff defines eligibility, but functional rescue is linked to photoreceptor preservation and that pediatric patients often have more viable cells and better potential for improvements. (testa2024voretigeneneparvovecfor pages 1-2)

12.4 Experimental / ongoing studies (examples)

ClinicalTrials.gov studies retrieved in this session include the pivotal trial and long-term follow-up/registry studies (e.g., NCT00999609, NCT03602820, NCT03597399, NCT04516369). (NCT00999609 chunk 2, OpenTargets Search: RPE65-related retinopathy,Leber congenital amaurosis,retinitis pigmentosa-RPE65)

12.5 MAXO suggestions

• Gene replacement therapy / gene augmentation therapy (for AAV-mediated subretinal delivery of RPE65). (testa2024voretigeneneparvovecfor pages 1-2, fischer2024realworldsafetyand pages 1-2)
• Vitrectomy and subretinal injection as procedural components of delivery. (testa2024voretigeneneparvovecfor pages 1-2)

13. Prevention

No primary prevention (in the sense of preventing disease onset) is established for this monogenic condition in the retrieved evidence. Secondary/tertiary prevention centers on: - Genetic counseling and cascade testing in families (implied by autosomal recessive inheritance and diagnostic emphasis). (stepanova2023amoleculargenetic pages 1-2, han2023voretigeneneparvovecfor pages 1-2) - Early diagnosis and referral to assess eligibility for gene therapy while retinal cells remain viable. (testa2024voretigeneneparvovecfor pages 1-2, NCT00999609 chunk 2)

14. Other Species / Natural Disease

The retrieved evidence references long-duration treatment effects in canine disease models for RPE65 gene replacement (effects lasting nearly a decade), supporting comparative biology, but does not provide explicit taxonomy identifiers in the excerpt. (leroy2023genetherapyfor pages 1-2)

15. Model Organisms

The retrieved evidence indicates extensive animal-model work and reports long-term efficacy in canine models; a 2023 review included 71 animal-model gene-therapy publications and notes rAAV genome episomal persistence. (leroy2023genetherapyfor pages 1-2)

Recent Developments (2023–2024 highlights)

1. Real-world registry scale-up: PERCEIVE provides the largest prospective post-authorization real-world dataset to date (103 patients) with quantified safety (chorioretinal atrophy 12.6%) and sustained FST improvements to 2 years. (fischer2024realworldsafetyand pages 1-2)
2. Eligibility and implementation challenges: a 2024 scoping review synthesizes real-world variability and underscores that photoreceptor viability and pediatric timing are key determinants, with no universal structural cutoff for eligibility. (testa2024voretigeneneparvovecfor pages 1-2)
3. Population-specific variant catalogs expanding: 2023 national cohort work adds novel variants and defines high-frequency alleles in Russia (three variants = 41.8% of affected chromosomes), supporting country-level screening strategies. (stepanova2023amoleculargenetic pages 1-2)

Limitations of this Report

• Some requested identifiers (Orphanet, ICD-10/ICD-11, MeSH) and several categories (environmental risk factors, epigenetics, modifier genes) were not explicitly present in the retrieved full-text excerpts, and are therefore not asserted here.
• This report emphasizes sources successfully retrieved in this tool session; it is not an exhaustive systematic review of all PubMed literature.

References

1. (stepanova2023amoleculargenetic pages 1-2): Anna Stepanova, Natalya Ogorodova, Vitaly Kadyshev, Olga Shchagina, Sergei Kutsev, and Aleksandr Polyakov. A molecular genetic analysis of rpe65-associated forms of inherited retinal degenerations in the russian federation. Genes, 14:2056, Nov 2023. URL: https://doi.org/10.3390/genes14112056, doi:10.3390/genes14112056. This article has 5 citations.

2. (han2023voretigeneneparvovecfor pages 1-2): Jinu Han, Kwangsic Joo, Ungsoo Samuel Kim, Se Joon Woo, Eun Kyoung Lee, Joo Yong Lee, Tae Kwann Park, Sang Jin Kim, and Suk Ho Byeon. Voretigene neparvovec for the treatment of rpe65-associated retinal dystrophy: consensus and recommendations from the korea rpe65-ird consensus paper committee. Korean Journal of Ophthalmology, 37:166-186, Apr 2023. URL: https://doi.org/10.3341/kjo.2023.0008, doi:10.3341/kjo.2023.0008. This article has 6 citations.

3. (leroy2023genetherapyfor pages 1-2): Bart P. Leroy, M. Dominik Fischer, John G. Flannery, Robert E. MacLaren, Deniz Dalkara, Hendrik P.N. Scholl, Daniel C. Chung, Claudio Spera, Daniel Viriato, and Judit Banhazi. Gene therapy for inherited retinal disease: long-term durability of effect. Ophthalmic Research, 66:179-196, Sep 2023. URL: https://doi.org/10.1159/000526317, doi:10.1159/000526317. This article has 81 citations and is from a peer-reviewed journal.

4. (OpenTargets Search: RPE65-related retinopathy,Leber congenital amaurosis,retinitis pigmentosa-RPE65): Open Targets Query (RPE65-related retinopathy,Leber congenital amaurosis,retinitis pigmentosa-RPE65, 3 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

5. (NCT00999609 chunk 2): Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis. Spark Therapeutics, Inc.. 2012. ClinicalTrials.gov Identifier: NCT00999609

6. (testa2024voretigeneneparvovecfor pages 1-2): Francesco Testa, Giacomo Bacci, Benedetto Falsini, Giancarlo Iarossi, Paolo Melillo, Dario Pasquale Mucciolo, Vittoria Murro, Anna Paola Salvetti, Andrea Sodi, Giovanni Staurenghi, and Francesca Simonelli. Voretigene neparvovec for inherited retinal dystrophy due to rpe65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice. Eye, 38:2504-2515, Apr 2024. URL: https://doi.org/10.1038/s41433-024-03065-6, doi:10.1038/s41433-024-03065-6. This article has 38 citations and is from a peer-reviewed journal.

7. (fischer2024realworldsafetyand pages 1-2): M. Dominik Fischer, Francesca Simonelli, Jayashree Sahni, Frank G. Holz, Rainer Maier, Christina Fasser, Andrea Suhner, Daniel P. Stiehl, Bee Chen, Isabelle Audo, and Bart P. Leroy. Real-world safety and effectiveness of voretigene neparvovec: results up to 2 years from the prospective, registry-based perceive study. Biomolecules, 14:122, Jan 2024. URL: https://doi.org/10.3390/biom14010122, doi:10.3390/biom14010122. This article has 64 citations.

8. (testa2022rpe65associatedretinopathiesin pages 1-2): Francesco Testa, Vittoria Murro, Sabrina Signorini, Leonardo Colombo, Giancarlo Iarossi, Francesco Parmeggiani, Benedetto Falsini, Anna Paola Salvetti, Raffaella Brunetti-Pierri, Giorgia Aprile, Chiara Bertone, Agnese Suppiej, Francesco Romano, Marianthi Karali, Simone Donati, Paolo Melillo, Andrea Sodi, Luciano Quaranta, Luca Rossetti, Luca Buzzonetti, Marzio Chizzolini, Stanislao Rizzo, Giovanni Staurenghi, Sandro Banfi, Claudio Azzolini, and Francesca Simonelli. rpe65-associated retinopathies in the italian population: a longitudinal natural history study. Investigative Opthalmology & Visual Science, 63:13, Feb 2022. URL: https://doi.org/10.1167/iovs.63.2.13, doi:10.1167/iovs.63.2.13. This article has 23 citations.

9. (chiu2021anupdateon pages 5-6): Wei Chiu, Ting-Yi Lin, Yun-Chia Chang, Henkie Isahwan-Ahmad Mulyadi Lai, Shen-Che Lin, Chun Ma, Aliaksandr A. Yarmishyn, Shiuan-Chen Lin, Kao-Jung Chang, Yu-Bai Chou, Chih-Chien Hsu, Tai-Chi Lin, Shih-Jen Chen, Yueh Chien, Yi-Ping Yang, and De-Kuang Hwang. An update on gene therapy for inherited retinal dystrophy: experience in leber congenital amaurosis clinical trials. International Journal of Molecular Sciences, 22:4534, Apr 2021. URL: https://doi.org/10.3390/ijms22094534, doi:10.3390/ijms22094534. This article has 128 citations.

10. (han2023voretigeneneparvovecfor pages 2-4): Jinu Han, Kwangsic Joo, Ungsoo Samuel Kim, Se Joon Woo, Eun Kyoung Lee, Joo Yong Lee, Tae Kwann Park, Sang Jin Kim, and Suk Ho Byeon. Voretigene neparvovec for the treatment of rpe65-associated retinal dystrophy: consensus and recommendations from the korea rpe65-ird consensus paper committee. Korean Journal of Ophthalmology, 37:166-186, Apr 2023. URL: https://doi.org/10.3341/kjo.2023.0008, doi:10.3341/kjo.2023.0008. This article has 6 citations.

11. (kumaran2017lebercongenitalamaurosisearlyonset pages 1-2): Neruban Kumaran, Anthony T Moore, Richard G Weleber, and Michel Michaelides. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. The British Journal of Ophthalmology, 101:1147-1154, Jul 2017. URL: https://doi.org/10.1136/bjophthalmol-2016-309975, doi:10.1136/bjophthalmol-2016-309975. This article has 412 citations.

12. (testa2022rpe65associatedretinopathiesin pages 3-4): Francesco Testa, Vittoria Murro, Sabrina Signorini, Leonardo Colombo, Giancarlo Iarossi, Francesco Parmeggiani, Benedetto Falsini, Anna Paola Salvetti, Raffaella Brunetti-Pierri, Giorgia Aprile, Chiara Bertone, Agnese Suppiej, Francesco Romano, Marianthi Karali, Simone Donati, Paolo Melillo, Andrea Sodi, Luciano Quaranta, Luca Rossetti, Luca Buzzonetti, Marzio Chizzolini, Stanislao Rizzo, Giovanni Staurenghi, Sandro Banfi, Claudio Azzolini, and Francesca Simonelli. rpe65-associated retinopathies in the italian population: a longitudinal natural history study. Investigative Opthalmology & Visual Science, 63:13, Feb 2022. URL: https://doi.org/10.1167/iovs.63.2.13, doi:10.1167/iovs.63.2.13. This article has 23 citations.

13. (testa2022rpe65associatedretinopathiesin pages 4-6): Francesco Testa, Vittoria Murro, Sabrina Signorini, Leonardo Colombo, Giancarlo Iarossi, Francesco Parmeggiani, Benedetto Falsini, Anna Paola Salvetti, Raffaella Brunetti-Pierri, Giorgia Aprile, Chiara Bertone, Agnese Suppiej, Francesco Romano, Marianthi Karali, Simone Donati, Paolo Melillo, Andrea Sodi, Luciano Quaranta, Luca Rossetti, Luca Buzzonetti, Marzio Chizzolini, Stanislao Rizzo, Giovanni Staurenghi, Sandro Banfi, Claudio Azzolini, and Francesca Simonelli. rpe65-associated retinopathies in the italian population: a longitudinal natural history study. Investigative Opthalmology & Visual Science, 63:13, Feb 2022. URL: https://doi.org/10.1167/iovs.63.2.13, doi:10.1167/iovs.63.2.13. This article has 23 citations.

14. (testa2022rpe65associatedretinopathiesin pages 7-8): Francesco Testa, Vittoria Murro, Sabrina Signorini, Leonardo Colombo, Giancarlo Iarossi, Francesco Parmeggiani, Benedetto Falsini, Anna Paola Salvetti, Raffaella Brunetti-Pierri, Giorgia Aprile, Chiara Bertone, Agnese Suppiej, Francesco Romano, Marianthi Karali, Simone Donati, Paolo Melillo, Andrea Sodi, Luciano Quaranta, Luca Rossetti, Luca Buzzonetti, Marzio Chizzolini, Stanislao Rizzo, Giovanni Staurenghi, Sandro Banfi, Claudio Azzolini, and Francesca Simonelli. rpe65-associated retinopathies in the italian population: a longitudinal natural history study. Investigative Opthalmology & Visual Science, 63:13, Feb 2022. URL: https://doi.org/10.1167/iovs.63.2.13, doi:10.1167/iovs.63.2.13. This article has 23 citations.

15. (leroy2023genetherapyfor pages 8-9): Bart P. Leroy, M. Dominik Fischer, John G. Flannery, Robert E. MacLaren, Deniz Dalkara, Hendrik P.N. Scholl, Daniel C. Chung, Claudio Spera, Daniel Viriato, and Judit Banhazi. Gene therapy for inherited retinal disease: long-term durability of effect. Ophthalmic Research, 66:179-196, Sep 2023. URL: https://doi.org/10.1159/000526317, doi:10.1159/000526317. This article has 81 citations and is from a peer-reviewed journal.

16. (astuti2016comprehensivegenotypingreveals pages 6-7): Galuh D N Astuti, Mette Bertelsen, Markus N Preising, Muhammad Ajmal, Birgit Lorenz, Sultana M H Faradz, Raheel Qamar, Rob W J Collin, Thomas Rosenberg, and Frans P M Cremers. Comprehensive genotyping reveals rpe65 as the most frequently mutated gene in leber congenital amaurosis in denmark. European Journal of Human Genetics, 24:1071-1079, Dec 2016. URL: https://doi.org/10.1038/ejhg.2015.241, doi:10.1038/ejhg.2015.241. This article has 98 citations and is from a domain leading peer-reviewed journal.

17. (astuti2016comprehensivegenotypingreveals pages 8-9): Galuh D N Astuti, Mette Bertelsen, Markus N Preising, Muhammad Ajmal, Birgit Lorenz, Sultana M H Faradz, Raheel Qamar, Rob W J Collin, Thomas Rosenberg, and Frans P M Cremers. Comprehensive genotyping reveals rpe65 as the most frequently mutated gene in leber congenital amaurosis in denmark. European Journal of Human Genetics, 24:1071-1079, Dec 2016. URL: https://doi.org/10.1038/ejhg.2015.241, doi:10.1038/ejhg.2015.241. This article has 98 citations and is from a domain leading peer-reviewed journal.

18. (kiraly2023outcomesandadverse pages 5-8): Peter Kiraly, Charles L. Cottriall, Laura J. Taylor, Jasleen K. Jolly, Jasmina Cehajic-Kapetanovic, Imran H. Yusuf, Cristina Martinez-Fernandez de la Camara, Morag Shanks, Susan M. Downes, Robert E. MacLaren, and M. Dominik Fischer. Outcomes and adverse effects of voretigene neparvovec treatment for biallelic rpe65-mediated inherited retinal dystrophies in a cohort of patients from a single center. Biomolecules, 13:1484, Oct 2023. URL: https://doi.org/10.3390/biom13101484, doi:10.3390/biom13101484. This article has 28 citations.

19. (kiraly2023outcomesandadverse pages 1-2): Peter Kiraly, Charles L. Cottriall, Laura J. Taylor, Jasleen K. Jolly, Jasmina Cehajic-Kapetanovic, Imran H. Yusuf, Cristina Martinez-Fernandez de la Camara, Morag Shanks, Susan M. Downes, Robert E. MacLaren, and M. Dominik Fischer. Outcomes and adverse effects of voretigene neparvovec treatment for biallelic rpe65-mediated inherited retinal dystrophies in a cohort of patients from a single center. Biomolecules, 13:1484, Oct 2023. URL: https://doi.org/10.3390/biom13101484, doi:10.3390/biom13101484. This article has 28 citations.

20. (leroy2023genetherapyfor pages 7-8): Bart P. Leroy, M. Dominik Fischer, John G. Flannery, Robert E. MacLaren, Deniz Dalkara, Hendrik P.N. Scholl, Daniel C. Chung, Claudio Spera, Daniel Viriato, and Judit Banhazi. Gene therapy for inherited retinal disease: long-term durability of effect. Ophthalmic Research, 66:179-196, Sep 2023. URL: https://doi.org/10.1159/000526317, doi:10.1159/000526317. This article has 81 citations and is from a peer-reviewed journal.

21. (leroy2023genetherapyfor media 51c99434): Bart P. Leroy, M. Dominik Fischer, John G. Flannery, Robert E. MacLaren, Deniz Dalkara, Hendrik P.N. Scholl, Daniel C. Chung, Claudio Spera, Daniel Viriato, and Judit Banhazi. Gene therapy for inherited retinal disease: long-term durability of effect. Ophthalmic Research, 66:179-196, Sep 2023. URL: https://doi.org/10.1159/000526317, doi:10.1159/000526317. This article has 81 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01